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One must admit that a short title extremely rarely can reflect the content of a huge book 
in a satisfactory way. In the case of the latest book by Daniel Carpenter, however, that 
exception has occured: there is no better manner to describe the role, destiny, and reality 
of the U.S. Food and Drug Administration, but by the two key words: reputation and 
power.
Where does that particular interest to study the history of a regulatory agency come 
from? The author Daniel P. Carpenter, the Allie S. Freed Professor of Government at 
Harvard University, offers an explanation himself: he has been influenced by his grandfa-
ther, a city health commissioner of Milwaukee, and by his mother, a radiologist, who 
both taught him about the entwinement of public health, science, and politics. Their 
stories have revealed to Daniel Carpenter also that public health must combine benevo-
lence and weighedness with resoluteness and a certain degree of coercion, in order to ob-
tain the best results for a community. Carpenter’s previous book, The Forging of Bureau-
cratic Autonomy: Reputations, Networks, and Policy Innovation in Executive Agencies, 
1862-1928 (also published by Princeton University Press, in 2001), was a milestone in 
the field: the present work, devoted to the FDA, has been a logical continuation of the 
same specific and thorough pursue.
In his study, Carpenter first considers theory of regulation, analysing the notions and 
practice of „reputation“ and „public interest“, as well as the risks of based-upon public 
decisions. He justly stresses the „paradox“ of the American society, being at the same 
time „anti-bureaucratic“ and obedient to federal regulatory agency. Carpenter’s fascina-
tion with the regulatory power executed by the FDA lengthens out to all its aspects – di-
rective, gatekeeping, and conceptual – as well as to its features eventually adopted in 
other nations. A particularly inspiring sub-chapter is devoted to „organizational reputa-
tion“, that is, to the reputation an organization reaches thanks to its specific capacities 
and roles.
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In the first part of the book, entitled Organizational empowerment and challenge, Carpen-
ter departs from the very beginning of the regulatory statutes in the USA – the Federal 
Food, Drug and Cosmetic Act of 1938, resulting from the New Deal policy, but also 
from tragic experiences with elixir sulfanilamide (1937). In the following post-war peri-
od (1944-1961), the focus was the establishment of protocol and procedure in devising 
new drugs. The end of that period was marked by the thalidomide affair with an epi-
demic of congenital defects in Europe and Australia: in the US, launched was the name 
of Frances Kelsey, the FDA medical officer who had refused to approve thalidomide (Ke-
vadon) for the USA market. Subsequently, in 1962 and 1963, new standards for FDA 
drug review and new rules for clinical trials were introduced. The range of reputation the 
agency reached at that point might be illustrated by the fact that, since 1964 until 1967, 
25 new FDA public advisory committees were authorized. Congressional hearings and 
judicial affirmation furtherly extended the agency authority. The late twentieth century 
brought new regulatory challanges related to dietary supplements, cancer and AIDS 
therapy.
In the second part of the book – Pharmaceutical regulation and its audiences –stressed and 
analysed has basically been the particular position the FDA created on the crossroad of 
scientific research and political regulation, as well as the ways the FDA has faught to pre-
serve its own autonomy in front of the stratagems of powerful pharmaceutic industry 
and approval pressures.
What can one learn from the Carpenter account? Probably the most important message 
is that regulatory administration is not something that can be developed easily and rap-
idly: decades of experience and protocolizing, lessons from domestic- and foreign-market 
tragedies, but, before all, a highly standardized scrutiny, result in an immense pool of 
reputation that becomes entitled to exercise power over community and in the commu-
nity interest. Carpenter’s story is a story of continuity and a proof that quantity, if cor-
rectly guided and honestly monitored, must evolve into quality.
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